# ELIANA (NCT02435849)

> Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02435849
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: B-cell Acute Lymphoblastic Leukemia
- Interventions: CTL019
- Enrollment: 80
- Primary outcome: Percentage of Participants With Overall Remission Rate (ORR) as Determined by Independent Review Committee (IRC) Assessment.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- Podcasts: 4
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=eliana-nct02435849

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02435849", "email": "<work email>"}; the inbox owner confirms by the emailed link.